Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Evotec SE    EVT   DE0005664809

EVOTEC SE

(EVT)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Xetra
06/19/2019 06/20/2019 06/21/2019 06/24/2019 06/25/2019 Date
24.27(c) 24.6(c) 24.32(c) 24.6(c) 23.93 Last
1 090 367 991 081 1 146 984 600 841 396 044 Volume
+1.80% +1.36% -1.14% +1.15% -2.72% Change
More quotes
Financials (EUR)
Sales 2019 417 M
EBIT 2019 73,7 M
Net income 2019 53,5 M
Finance 2019 3,00 M
Yield 2019 -
Sales 2020 472 M
EBIT 2020 83,2 M
Net income 2020 55,1 M
Finance 2020 76,7 M
Yield 2020 -
P/E ratio 2019 67,08
P/E ratio 2020 65,60
EV / Sales2019 8,82x
EV / Sales2020 7,66x
Capitalization 3 686 M
More Financials
Company
Evotec specializes in research and development services for the pharmaceutical and biotechnological industries. The group's activity is organized around 3 areas: - development of broadband screening systems; - research and development of pharmaceutical products: for the neurologic, oncologic,... 
More about the company
Surperformance© ratings of Evotec SE
Trading Rating : Investor Rating :
More Ratings
Latest news on EVOTEC SE
06/24EVOTEC : Sensyne health, the university of oxford, osi, and oui create new bridg..
EQ
06/20EVOTEC : Resolutions of the Annual General Meeting 2019 of Evotec SE
AQ
06/19EVOTEC : Resolutions of the annual general meeting 2019 of evotec se
EQ
06/13EVOTEC : bags US$23.8m to fight tuberculosis
AQ
06/12EVOTEC : bags $23.8m to fight tuberculosis
AQ
06/11EVOTEC : receives $ 23.8 m grant to join the global fight against tuberculosis
AQ
06/10EVOTEC : Receives $ 23.8 m grant to join the global fight against tuberculosis
EQ
06/06EVOTEC : and Celgene further expand iPSC collaboration including new cell type
AQ
06/05EVOTEC : And celgene further expand ipsc collaboration including new cell type
EQ
05/31EVOTEC SE : Release according to Article 41 of the WpHG [the German Securities T..
EQ
More news
Analyst Recommendations on EVOTEC SE
More recommendations
Stock Trading Strategies
EVOTEC AG - 05/10
Good timing to go long again
BUY
More Stock Trading Analysis
Sector news : Biotechnology & Medical Research - NEC
06/21Regeneron, Sanofi Report Positive Topline Phase 2 Asthma Results
DJ
06/20EXELIXIS : Phase 3 Combination Study for Melanoma Didn't Meet Primary Endpoint
DJ
06/19PFIZER : Fitch Puts Pfizer on Watch Negative, Notes Leverage Increase
DJ
06/19GILEAD SCIENCES : Sets Collaboration With Nurix Therapeutics
DJ
06/18WHAT'S NEWS : Business & Finance -- WSJ
DJ
More sector news : Biotechnology & Medical Research - NEC
Chart EVOTEC SE
Duration : Period :
Evotec SE Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EVOTEC SE
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 26,9 €
Spread / Average Target 9,1%
EPS Revisions
Managers
NameTitle
Werner Lanthaler Chief Executive Officer
Wolfgang Plischke Chairman-Supervisory Board
Craig L. Johnstone Chief Operating Officer & Member-Management Board
Enno Spillner Chief Financial Officer
Cord E. Dohrmann Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
EVOTEC SE41.66%3 664
IQVIA HOLDINGS INC35.52%26 223
LONZA GROUP28.39%24 012
CELLTRION, INC.--.--%20 953
INCYTE CORPORATION36.69%17 061
EXACT SCIENCES CORPORATION80.30%13 037